Skye Bioscience, Common Stock Investor Sentiment

SKYE Stock  USD 2.85  0.01  0.35%   
About 67% of Skye Bioscience,'s investor base is looking to short. The analysis of the overall investor sentiment regarding Skye Bioscience, Common suggests that many traders are alarmed. The current market sentiment, together with Skye Bioscience,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Skye Bioscience, Common stock news signals to limit their universe of possible portfolio assets.
  

Skye Bioscience, Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Skye Bioscience, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at aol.com         
The postie photographing Skye on his rounds
news
over six months ago at benzinga.com         
Skye Bioscience to Present at Jefferies Global Healthcare Conference
benzinga news
over six months ago at news.google.com         
Skye Bioscience, Inc.s last weeks 13 percent decline must have disappointed private equity firms who...
Google News at Macroaxis
over six months ago at news.google.com         
Skye Bioscience Moves to Nasdaq, Hits Milestone in Clinical Program - Proactive Investors USA
Google News at Macroaxis
over six months ago at news.google.com         
Skye Bioscience Announces 40 Million Private Placement Equity Financing - The Globe and Mail
Google News at Macroaxis
over six months ago at news.google.com         
Skye Bioscience Uplists to The Nasdaq Global Market - GlobeNewswire
Google News at Macroaxis
over six months ago at news.google.com         
Aequus Pharmaceuticals Shares Up 33.3 percent - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Skye Bioscience Announces 7.0 Million Registered Direct Offering - The Globe and Mail
Google News at Macroaxis
over six months ago at news.google.com         
Emerald Bioscience Hits New 12-Month High at 14.95 - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Skye Bioscience secures 40 million in private placement By Investing.com - Investing.com Canada
Google News at Macroaxis
over six months ago at news.google.com         
Neurocrine Biosciences, Inc. Insider Sells 148117.44 in Stock - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Skye Bioscience Announces 50.25 Million Private Placement Equity Financing - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Systemic Sclerosis Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 - Benzinga
Google News at Macroaxis
over a year ago at news.google.com         
DelveInsight Highlights Major Advances, Transformative Therapies, and 45 Leading Players Wheeling th...
Google News at Macroaxis
over a year ago at news.google.com         
Janssen sticks with Cidaras flu med but intends to hand over rights ... - FierceBiotech
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Skye Bioscience, that are available to investors today. That information is available publicly through Skye media outlets and privately through word of mouth or via Skye internal channels. However, regardless of the origin, that massive amount of Skye data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Skye Bioscience, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Skye Bioscience, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Skye Bioscience,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Skye Bioscience, alpha.

Skye Bioscience, Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Jenkins Annalisa of 70000 shares of Skye Bioscience, at 5.15 subject to Rule 16b-3
10/28/2024
2
Acquisition by Dhillon Punit of 110000 shares of Skye Bioscience, at 0.0171 subject to Rule 16b-3
11/01/2024
3
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
11/07/2024
4
Skye Bioscience Surpasses 50 percent Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
11/14/2024
5
Disposition of 307 shares by Grayson Paul A. of Skye Bioscience, at 5.55 subject to Rule 16b-3
11/15/2024
6
Disposition of 86244 shares by Grayson Paul A. of Skye Bioscience, at 4.99 subject to Rule 16b-3
11/18/2024
7
Skye Bioscience chief development officer sells shares worth 97,721
11/20/2024
8
British Design Firm Forecasts 2025 Color Trends
11/21/2024
9
Callous coward Finlay MacDonald jailed for life after murdering his brother-in-law
11/29/2024
10
Insider Trading
12/09/2024
11
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
12/19/2024

Complementary Tools for Skye Stock analysis

When running Skye Bioscience,'s price analysis, check to measure Skye Bioscience,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Skye Bioscience, is operating at the current time. Most of Skye Bioscience,'s value examination focuses on studying past and present price action to predict the probability of Skye Bioscience,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Skye Bioscience,'s price. Additionally, you may evaluate how the addition of Skye Bioscience, to your portfolios can decrease your overall portfolio volatility.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk